Armata Pharmaceuticals receives $2.5M additional non-dilutive DoD funding for AP-SA02

What's the deal? Armata PharmaceuticalsDealroom has a profile for this one. Try Dealroom → has received an additional $2.5 million in non-dilutive grant funding from the US Department of Defense to advance its lead candidate, AP-SA02.

The drug is a phage-based therapy for complicated Staphylococcus aureus bacteremia, a severe and often deadly bloodstream infection.

The award, routed through the Medical Technology Enterprise Consortium and managed by the Naval Medical Research Command, brings total Department of Defense backing to $28.7 million.

Why now? The new money funds Phase 3 readiness. Armata plans to begin a Phase 3 superiority study of intravenous AP-SA02 in the second half of 2026.

Positive Phase 2a results were presented at IDWeek 2025 last October, clearing the path to the next stage.

"The DoD has been a strong and valued partner in the development of AP-SA02," said Deborah Birx, chief executive officer of Armata.

What could go wrong? Phase 3 trials are expensive, slow, and far from guaranteed. The funding covers readiness, not the full cost of the study.

AP-SA02 has Fast Track and Qualified Infectious Disease Product designations from the US Food and Drug Administration, but neither ensures approval.

The signal: The Department of Defense's repeated, non-dilutive backing — now $28.7 million in total — reflects how governments are increasingly underwriting antimicrobial-resistance research that private capital often deems too slow and risky to fund alone. For Armata, a mature-stage biotech, this federal support helps de-risk an expensive path to Phase 3 without diluting shareholders.

Image credit: "Phage" by pasukaru76 is marked with CC0 1.0. To view the terms, visit https://creativecommons.org/publicdomain/zero/1.0/.